EconomicsSource: The Hindu
Biopharma SHAKTI Scheme: Advancing India's Biopharma Sector
Thursday, 26 March 2026
Read Original ArticleKey Points
The Union Budget 2026-27 introduced the Biopharma SHAKTI scheme to enhance India's biopharmaceutical capabilities. This initiative is crucial for UPSC aspirants, particularly for GS Paper 3, as it addresses economic development and technological innovation. Last Updated: 26-03-2026
Key Facts About Biopharma SHAKTI Scheme
- Definition: The Biopharma SHAKTI scheme aims to transition India from a leader in generic drugs to a global powerhouse for high-value biologics and biosimilars.
- Objective: Aligns with the National Biopharma Mission 2017 to transform India into a USD 100 billion leading global biotech industry by 2025.
- Financial Outlay: Rs 10,000 crore allocated over 5 years starting FY 2026-27.
- Disease Focus: Prioritizes affordable domestic production of therapies for non-communicable diseases like cancer and diabetes.
- Manufacturing Shift: Encourages adoption of NAMs like organoids and 3D bioprinting to reduce costs and improve drug safety.
- Infrastructure & Academia: Establishment of 3 new NIPERs and upgrading 7 existing ones into centers of excellence.
- Regulatory Reform: Strengthening CDSCO with a dedicated "Scientific Review Cadre" to align approval timelines internationally.
- Significance: Addresses the rise of NCDs, which account for 63% of all deaths in India, and potential US tariffs on pharmaceuticals.
India's Pharmaceutical Sector
India is the 3rd largest pharmaceutical producer by volume and 11th by value, supplying 20% of global generic medicines. The sector reached an annual turnover of Rs 4.72 lakh crore in FY25, with a 7% CAGR in exports over the last decade. India is also competitive in medical devices, exporting to 187 countries.
UPSC Relevance
- GS Paper 3: Economic development, technological innovation, and health sector advancements.
- Prelims: Questions on scheme objectives, financial outlay, and disease focus.
- Mains: Analytical themes on India's biopharmaceutical capabilities and global positioning.
- Essay Paper: Topics on innovation in healthcare and economic growth.
FAQ Section
- What is the Biopharma SHAKTI Scheme? The Biopharma SHAKTI scheme is a government initiative to enhance India's capabilities in high-value biologics and biosimilars, aligning with the National Biopharma Mission 2017.
- Why is the Biopharma SHAKTI Scheme important? It aims to transform India into a leading global biotech industry, addressing the rise of non-communicable diseases and potential international trade challenges.
- What are the key features of the Biopharma SHAKTI Scheme? Key features include a Rs 10,000 crore financial outlay, focus on non-communicable diseases, adoption of NAMs, and strengthening of regulatory frameworks.
Detailed Coverage
- Biopharma SHAKTI Scheme aims to make India a leader in biologics and biosimilars.
- Aligned with the National Biopharma Mission to reach a USD 100 billion biotech industry by 2025.
- Government allocated Rs 10,000 crore over 5 years for advanced biopharmaceuticals.
- Focus on affordable therapies for non-communicable diseases like cancer and diabetes.
- Encourages adoption of New Approach Methodologies (NAMs) in manufacturing.
- Establishing 3 new NIPERs and upgrading 7 existing ones.
- Creating a network of over 1,000 clinical trial sites.
- Strengthening CDSCO with a dedicated review cadre.
- Addresses rising deaths from NCDs, accounting for 63% of deaths in India.
- India is the 3rd largest pharmaceutical producer by volume.
- Pharmaceutical sector reached an annual turnover of Rs 4.72 lakh crore in FY25.
- India is competitive in exporting high-end medical devices.
- Biologics are large, complex drugs produced from living systems.
- Biosimilars are similar to approved biologics, cheaper by 30%-70%.
- NAMs prioritize human-relevant data, reducing animal testing.
- NAMs improve drug development efficiency and enable precision medicine.
Economics